- Home
- AMBO vs IMRN Comparison
AMBO vs IMRN Comparison
Compare AMBO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- IMRN
- Stock Information
- Founded
- AMBO 2000
- IMRN 1994
- Country
- AMBO United States
- IMRN Australia
- Employees
- AMBO N/A
- IMRN N/A
- Industry
- AMBO Other Consumer Services
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- IMRN Health Care
- Exchange
- AMBO Nasdaq
- IMRN Nasdaq
- Market Cap
- AMBO 8.3M
- IMRN 9.2M
- IPO Year
- AMBO 2010
- IMRN N/A
- Fundamental
- Price
- AMBO $3.66
- IMRN $1.93
- Analyst Decision
- AMBO
- IMRN Strong Buy
- Analyst Count
- AMBO 0
- IMRN 1
- Target Price
- AMBO N/A
- IMRN $5.00
- AVG Volume (30 Days)
- AMBO 33.4K
- IMRN 49.5K
- Earning Date
- AMBO 08-05-2025
- IMRN 08-29-2025
- Dividend Yield
- AMBO N/A
- IMRN N/A
- EPS Growth
- AMBO N/A
- IMRN N/A
- EPS
- AMBO 0.69
- IMRN N/A
- Revenue
- AMBO $9,699,000.00
- IMRN $4,777,422.00
- Revenue This Year
- AMBO N/A
- IMRN N/A
- Revenue Next Year
- AMBO N/A
- IMRN N/A
- P/E Ratio
- AMBO $5.23
- IMRN N/A
- Revenue Growth
- AMBO 23.73
- IMRN 48.63
- 52 Week Low
- AMBO $1.00
- IMRN $1.50
- 52 Week High
- AMBO $5.55
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- AMBO 57.92
- IMRN 59.97
- Support Level
- AMBO $2.91
- IMRN $1.80
- Resistance Level
- AMBO $3.80
- IMRN $1.93
- Average True Range (ATR)
- AMBO 0.36
- IMRN 0.07
- MACD
- AMBO -0.00
- IMRN 0.01
- Stochastic Oscillator
- AMBO 84.26
- IMRN 99.45
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.